VISX hyperopic LASIK treatment approved

Santa Clara, CA—CustomVue LASIK (VISX) performed with the WaveScan system and the STAR S4 excimer laser has become the first wavefront-guided laser treatment approved by the FDA for correction of hyperopia and hyperopic astigmatism.

Related Videos
Related Content

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Driving with glaucoma: Steering clear of vision issues

March 28th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Driving with glaucoma: Steering clear of vision issues

March 28th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Verana Health unveils Qdata Anti-VEGF Market Tracker

March 28th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Driving with glaucoma: Steering clear of vision issues

March 28th 2023
© 2023 MJH Life Sciences

All rights reserved.